Update on the development of new novel cancer immunotherapy
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
List view / Grid view
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.
2 June 2016 | By Victoria White, Digital Content Producer
Researchers have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme using ImmunoBody technology...
11 March 2016 | By Victoria White
Scancell is to collaborate with the Karolinska Institutet to explore the scientific and clinical role of citrullinated proteins in the treatment of cancer...